Sun Pharma Advanced Research Co (NSE:SPARC) 3-Year RORE % : 235.73% (As of Mar. 2026)


NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
67 GF Score
Price ₹264.60
GF Value ₹4,526.00
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co 3-Year RORE %?

Sun Pharma Advanced Research Co NSE:SPARC -4.67% 67 3-Year RORE % is 235.73 as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 67/100 and a GF Value™ of ₹4,526.00 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 939 Drug Manufacturers companies, Sun Pharma Advanced Research Co ranks better than 96.81% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Sun Pharma Advanced Research Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was 235.73%.

The industry rank for Sun Pharma Advanced Research Co's 3-Year RORE % or its related term are showing as below:

NSE:SPARC's 3-Year RORE % is ranked better than
96.81% of 939 companies
in the Drug Manufacturers industry
Industry Median: 3.06 vs NSE:SPARC: 235.73

Sun Pharma Advanced Research Co  (NSE:SPARC) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Sun Pharma Advanced Research Co 3-Year RORE % Related Terms


Sun Pharma Advanced Research Co 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co 3-Year RORE % Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.57 9.74 15.35 8.90 235.73

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.90 4.94 1.11 -9.72 235.73

NSE:SPARC vs ZTS, UTHR: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's 3-Year RORE % falls into.


NSE:SPARC
67GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co 3-Year RORE % Calculation

Sun Pharma Advanced Research Co's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 47.85--11.93 )/( 25.36-0 )
=59.78/25.36
=235.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 235.73 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a 3-Year RORE % of 235.73 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sun Pharma Advanced Research Co and its competitors. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #30 out of 939 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Sun Pharma Advanced Research Co's 3-Year RORE % too high?
Sun Pharma Advanced Research Co's current 3-Year RORE % is 235.73. The Drug Manufacturers industry median 3-Year RORE % is 3.06. Sun Pharma Advanced Research Co's value of 235.73 is 7603.6% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #30 out of 939 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #30 out of 939 companies for 3-Year RORE %. This places Sun Pharma Advanced Research Co in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.06. Sun Pharma Advanced Research Co's value of 235.73 is 7603.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.06, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current 3-Year RORE % of 235.73 is 7603.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current 3-Year RORE % is 235.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,526.00, compared to a current price of ₹264.60 — trading 94.2% below its estimated fair value. The current 3-Year RORE % is 235.73 and 7603.6% above the Drug Manufacturers industry median of 3.06. Sun Pharma Advanced Research Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current 3-Year RORE % is 235.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹264.60 is trading 94.2% below its estimated GF Value™ of ₹4,526.00. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • 3-Year RORE %: 235.73
  • GF Value™: ₹4,526.00 vs. price of ₹264.60 (94.2% below fair value)
  • GF Score™: 67/100 with 7 warning signs
  • Industry Position: 7603.6% above the Drug Manufacturers median (#30 of 939)

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
67GF Score

Get the complete analysis for NSE:SPARC

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹264.60
Price
₹4,526.00
GF Value